S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
BREAKING: Tiny biotech successfully treats blindness (Ad)
Federal student loan payments are starting again. Here's what you need to know
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
BREAKING: Tiny biotech successfully treats blindness (Ad)
A fight over precious groundwater in a rural California town is rooted in carrots
Facing increasing pressure from customers, some miners are switching to renewable energy
BREAKING: Tiny biotech successfully treats blindness (Ad)
The death toll in a collapsed gold mine in Zimbabwe expected to rise to 13, vice president says
Rishi Sunak needs to rally his flagging Conservatives. He hopes a dash of populism will do the trick
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
BREAKING: Tiny biotech successfully treats blindness (Ad)
Federal student loan payments are starting again. Here's what you need to know
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
BREAKING: Tiny biotech successfully treats blindness (Ad)
A fight over precious groundwater in a rural California town is rooted in carrots
Facing increasing pressure from customers, some miners are switching to renewable energy
BREAKING: Tiny biotech successfully treats blindness (Ad)
The death toll in a collapsed gold mine in Zimbabwe expected to rise to 13, vice president says
Rishi Sunak needs to rally his flagging Conservatives. He hopes a dash of populism will do the trick
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
BREAKING: Tiny biotech successfully treats blindness (Ad)
Federal student loan payments are starting again. Here's what you need to know
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
BREAKING: Tiny biotech successfully treats blindness (Ad)
A fight over precious groundwater in a rural California town is rooted in carrots
Facing increasing pressure from customers, some miners are switching to renewable energy
BREAKING: Tiny biotech successfully treats blindness (Ad)
The death toll in a collapsed gold mine in Zimbabwe expected to rise to 13, vice president says
Rishi Sunak needs to rally his flagging Conservatives. He hopes a dash of populism will do the trick
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
BREAKING: Tiny biotech successfully treats blindness (Ad)
Federal student loan payments are starting again. Here's what you need to know
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
BREAKING: Tiny biotech successfully treats blindness (Ad)
A fight over precious groundwater in a rural California town is rooted in carrots
Facing increasing pressure from customers, some miners are switching to renewable energy
BREAKING: Tiny biotech successfully treats blindness (Ad)
The death toll in a collapsed gold mine in Zimbabwe expected to rise to 13, vice president says
Rishi Sunak needs to rally his flagging Conservatives. He hopes a dash of populism will do the trick
NASDAQ:ABUS

Arbutus Biopharma (ABUS) Earnings Date, Estimates & Call Transcripts

$2.03
+0.03 (+1.50%)
(As of 09/29/2023 ET)
Compare
Today's Range
$1.99
$2.05
50-Day Range
$1.90
$2.20
52-Week Range
$1.86
$3.14
Volume
1.18 million shs
Average Volume
657,656 shs
Market Capitalization
$340.15 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.00

Earnings Summary

Upcoming
Earnings Date
Nov. 8Estimated
Actual EPS
(Aug. 3)
-$0.10 Beat By $0.02
Consensus EPS
(Aug. 3)
-$0.12
Skip Charts & View Estimated and Actual Earnings Data

ABUS Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

ABUS Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Arbutus Biopharma Analyst Forecasts

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20232($0.16)($0.14)($0.15)
Q2 20232($0.17)($0.12)($0.15)
Q3 20232($0.17)($0.11)($0.14)
Q4 20232($0.18)($0.10)($0.14)
FY 20238($0.68)($0.47)($0.58)
Q1 20241($0.17)($0.17)($0.17)
Q2 20241($0.17)($0.17)($0.17)
Q3 20241($0.18)($0.18)($0.18)
Q4 20241($0.18)($0.18)($0.18)
FY 20244($0.70)($0.70)($0.70)

ABUS Earnings Date and Information

Arbutus Biopharma last announced its quarterly earnings data on August 3rd, 2023. The biopharmaceutical company reported ($0.10) EPS for the quarter, topping the consensus estimate of ($0.12) by $0.02. The firm earned $4.65 million during the quarter, compared to the consensus estimate of $5.02 million. Arbutus Biopharma has generated ($0.46) earnings per share over the last year (($0.46) diluted earnings per share). Earnings for Arbutus Biopharma are expected to decrease in the coming year, from ($0.43) to ($0.49) per share. Arbutus Biopharma has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, November 8th, 2023 based off prior year's report dates.

Arbutus Biopharma Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
11/8/2023
Estimated)
------- 
8/3/2023Q2 2023($0.12)($0.10)+$0.02($0.10)$5.02 million$4.65 million
5/4/2023Q1 2023($0.14)($0.10)+$0.04($0.10)$4.52 million$6.69 million
3/2/2023Q4 2022($0.14)($0.14)-($0.14)$6.31 million$6.25 million
11/9/2022Q3 2022($0.12)($0.12)-($0.12)$11.12 million$5.95 million
8/4/2022Q2 2022($0.13)($0.10)+$0.03($0.10)$5.37 million$14.24 million    
5/5/2022Q1 2022($0.13)($0.11)+$0.02($0.11)$5.77 million$12.58 million    
3/3/2022Q4 2021($0.16)($0.15)+$0.01($0.15)$3.39 million$3.21 million    
11/4/2021Q3 2021($0.24)($0.24)-($0.24)$2.36 million$3.34 million    
8/4/2021Q2 2021($0.21)($0.23)($0.02)($0.23)$2.07 million$2.33 million    
5/4/2021Q1 2021($0.23)($0.21)+$0.02($0.21)$3.87 million$2.11 million  
3/3/2021Q4 2020($0.22)($0.23)($0.01)($0.23)$2.12 million$2.39 million    
11/10/2020Q3 2020($0.22)($0.27)($0.05)($0.27)$1.81 million$1.52 million    












Arbutus Biopharma Earnings - Frequently Asked Questions

When is Arbutus Biopharma's earnings date?

Arbutus Biopharma has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, November 8th, 2023 based off last year's report dates. Learn more on ABUS's earnings history.

Did Arbutus Biopharma beat their earnings estimates last quarter?

In the previous quarter, Arbutus Biopharma (NASDAQ:ABUS) reported ($0.10) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.12) by $0.02. Learn more on analysts' earnings estimate vs. ABUS's actual earnings.

How much revenue does Arbutus Biopharma generate each year?

Arbutus Biopharma (NASDAQ:ABUS) has a recorded annual revenue of $39.02 million.

How much profit does Arbutus Biopharma generate each year?

Arbutus Biopharma (NASDAQ:ABUS) has a recorded net income of -$69.46 million. ABUS has generated -$0.46 earnings per share over the last four quarters.

What is Arbutus Biopharma's EPS forecast for next year?

Arbutus Biopharma's earnings are expected to decrease from ($0.43) per share to ($0.49) per share in the next year.


More Earnings Resources from MarketBeat

This page (NASDAQ:ABUS) was last updated on 10/1/2023 by MarketBeat.com Staff

My Account -